Glucocorticoid-induced skeletal muscle atrophy

International Journal of Biochemistry and Cell Biology

Volumn 45, Issue 10, 2013, Pages 2163-2172

  Schakman, O ^a   Kalista, S ^b   Barbe C ^b   Loumaye, A ^b   Thissen, J P ^b  

^a Institut de Neurosciences   (Belgium)

^b Faculté de Médecine   (Belgium)

Author keywords

Glucocorticoids; Insulin like Growth Factors; Myostatin; Protein synthesis; Protein turnover; Skeletal muscle

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 1; ALANYLGLUTAMINE; ATROGIN 1; CLENBUTEROL; CREATINE; GHRELIN; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; GLUTAMINE; GLYCOGEN SYNTHASE KINASE 3BETA; LEUCINE; MAMMALIAN TARGET OF RAPAMYCIN; MUSCLE PROTEIN; MUSCLE RING FINGER 1 PROTEIN; MYOSTATIN; NANDROLONE; PROTEASOME; S6 KINASE; SOMATOMEDIN C; TAURINE; TESTOSTERONE; TRANSCRIPTION FACTOR FOXO; UBIQUITIN;

ACETYLATION; DIET SUPPLEMENTATION; DRUG INDUCED DISEASE; DRUG MEGADOSE; ENZYME ACTIVE SITE; HUMAN; LYSOSOME; MUSCLE ATROPHY; MUSCLE HYPERTROPHY; NONHUMAN; PROTEIN DEGRADATION; PROTEIN SYNTHESIS; REVIEW; SKELETAL MUSCLE; TURNOVER TIME;

11Β-HSD1; 11Β-HYDROXYSTEROID DEHYDROGENASE TYPE 1; 4E-BP1; BCAA; BCAT; BRANCHED-CHAIN AMINO ACID; BRANCHED-CHAIN AMINO ACID AMINOTRANSFERASE; C/EBP; CCAAT/ENHANCER BINDING PROTEIN; EDL; EIF2B; EIF3F; EIF4E; EUKARYOTIC INITIATION FACTOR 2B; EUKARYOTIC TRANSLATION INITIATION FACTOR 3 SUBUNIT F; EUKARYOTIC TRANSLATION INITIATION FACTOR 4E; EUKARYOTIC TRANSLATION INITIATION FACTOR 4E-BINDING PROTEIN 1; EXTENSOR DIGITORUM LONGUS; FORKHEAD BOX O; FOXO; GADD45; GC; GHSR1; GLUCOCORTICOID RECEPTOR; GLUCOCORTICOID-RESPONSIVE ELEMENT; GLUCOCORTICOIDS; GLYCOGEN SYNTHASE KINASE 3Β; GR; GRE; GROWTH ARREST AND DNA DAMAGE; GROWTH HORMONE SECRETAGOGUE RECEPTOR 1; GSK3Β; HAT; HDAC; HISTONE ACETYLTRANSFERASES; HISTONE DEACETYLASES; HMB; IGF-I; INSULIN RECEPTOR SUBSTRATE 1; INSULIN-LIKE GROWTH FACTOR-I; INSULIN-LIKE GROWTH FACTORS; IRS-1; KLF-15; KRUPPEL-LIKE FACTOR 15; LC3; MAMMALIAN TARGET OF RAPAMYCIN; MICRORNA 1; MICROTUBULE-ASSOCIATED PROTEIN LIGHT CHAIN 3; MIR1; MSTN; MTOR; MURF-1; MUSCLE RING-FINGER PROTEIN-1; MYHC; MYOSIN HEAVY CHAIN; MYOSTATIN; NFΚB; NUCLEAR FACTOR-KAPPA B; PDK4; PHOSPHATIDYLINOSITOL 3′ KINASE; PI3K; PROTEIN SYNTHESIS; PROTEIN TURNOVER; PYRUVATE DEHYDROGENASE KINASE 4; REDD1; REGULATED IN DEVELOPMENT AND DNA DAMAGE RESPONSES 1; RIBOSOMAL PROTEIN KINASE 1; S6K1; SARM; SELECTIVE ANDROGEN RECEPTOR MODULATOR; SIRNA; SKELETAL MUSCLE; SMALL INTERFERING RNA; UBIQUITIN PROTEASOME SYSTEM; UPS; Β-HYDROXY-Β-METHYLBUTYRATE;

ANIMALS; GLUCOCORTICOIDS; HUMANS; MUSCULAR ATROPHY; PROTEIN BIOSYNTHESIS; SIGNAL TRANSDUCTION;

EID: 84885182624     PISSN: 13572725     EISSN: 18785875     Source Type: Journal    
DOI: 10.1016/j.biocel.2013.05.036     Document Type: Review

References (152)

1. Agbenyega ET, Wareham AC Effect of clenbuterol on skeletal muscle atrophy in mice induced by the glucocorticoid dexamethasone. Comparative Biochemistry Physiology Comparative Physiology 1992; 102:141-5.
2. Alamdari N, Aversa Z, Castillero E., Gurav A, Petkova V, Tizio S., et al Resveratrol prevents dexamethasone-induced expression of the muscle atrophy-related ubiquitin ligases atrogin-1 and MuRF1 in cultured myotubes through a SIRT1-dependent mechanism. Biochemical and Biophysical Research Communications 2012; 417:528-33.
3. Alamdari N, Aversa Z, Castillero E., Hasselgren PO Acetylation and deacetylation-novel factors in muscle wasting. Metabolism 2013; 62:1-11.
4. Allen DL, Loh AS Posttranscriptional mechanisms involving microRNA-27a and b contribute to fast-specific and glucocorticoid-mediated myostatin expression in skeletal muscle. American Journal of Physiology: Cell Physiology 2011; 300:C124-37.
5. Almon RR, DuBois DC, Yao Z, Hoffman E.P., Ghimbovschi S., Jusko WJ Microarray analysis of the temporal response of skeletal muscle to methylpred-nisolone: comparative analysis of two dosing regimens. Physiological Genomics 2007; 30:282-99.
6. Amirouche A, Durieux AC, Banzet S, Koulmann N., Bonnefoy R, Mouret C, et al Down-regulation of akt/mammalian target of rapamycin signaling pathway in response to myostatin overexpression in skeletal muscle. Endocrinology 2009; 150:286-94.
7. Armstrong DD, Wong VL, Esser KA. Expression of beta-catenin is necessary for physiological growth of adult skeletal muscle. American Journal of Physiology: Cell Physiology 2006; 291:C185-8.
8. Artaza JN, Bhasin S, Mallidis C., Taylor W, Ma K, Gonzalez-Cadavid NF. Endogenous expression and localization of myostatin and its relation to myosin heavy chain distribution in C2C12 skeletal muscle cells. Journal of Cellular Physiology 2002; 190:170-9.
9. Aversa Z, Alamdari N, Castillero E., Muscaritoli M, Rossi FF, Hasselgren PO beta-Hydroxy-beta-methylbutyrate (HMB) prevents dexamethasone-induced myotube atrophy. Biochemical and Biophysical Research Communications 2012; 423:739-43.
10. Awede BL, Thissen JP, Lebacq J. Role of IGF-I and IGFBPs in the changes of mass and phenotype induced in rat soleus muscle by clenbuterol. American Journal of Physiology: Endocrinology and Metabolism 2002; 282:E31-7.
11. Baehr LM, Furlow JD, Bodine SC Muscle sparing in muscle RING finger 1 null mice: response to synthetic glucocorticoids. Journal of Physiology 2011; 589:4759-76.
12. Barry SC, Gallagher CG Corticosteroids and skeletal muscle function in cystic fibrosis. Journal of Applied Physiology 2003; 95:1379-84.
13. Biedasek K, Andres J, Mai K., Adams S, Spuler S, Fielitz J., et al Skeletal muscle 11beta-HSD1 controls glucocorticoid-induced proteolysis and expression of E3 ubiquitin ligases atrogin-1 and MuRF1. PLoS One 2011; 6:e16674.
14. Bodine SC, Latres E, Baumhueter S., Lai VKM, Nunez L, Clarke B.A., et al Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 2001; 294:1704-8.
15. Braun TP, Zhu X, Szumowski M., Scott GD, Grossberg AJ, Levasseur PR, et al Central nervous system inflammation induces muscle atrophy via activation of the hypothalamic-pituitary-adrenal axis. Journal of Experimental Medicine 2011; 208:2449-63.
16. Bruce M, Constantin-Teodosiu D, Greenhaff P.L., Boobis LH, Williams C, Bowtell JL. Glutamine supplementation promotes anaplerosis but not oxidative energy delivery in human skeletal muscle. American Journal of Physiology: Endocrinology and Metabolism 2001; 280:E669-75.
17. Campos AR, Serafini LN, Sobreira C, Menezes LG, Martinez JA. Creatine intake attenuates corticosteroid-induced impairment of voluntary running in hamsters. Applied Physiology Nutrition and Metabolism 2006; 31:490-4.
18. Chamberlain W, Gonnella P, Alamdari N., Aversa Z, Hasselgren PO Multiple muscle wasting-related transcription factors are acetylated in dexamethasone-treated muscle cells. Biochemistry and Cell Biology 2012; 90:200-8.
19. Chen LF, Greene WC Assessing acetylation of NF-kappaB. Methods 2005; 36:368-75.
20. Cho JE, Fournier M, Da X., Lewis MI Time course expression of Foxo transcription factors in skeletal muscle following corticosteroid administration. Journal of Applied Physiology 2010; 108:137-45.
21. Clarke BA, Drujan D, Willis M.S., Murphy LO, Corpina RA, Burova E, et al The E3 Ligase MuRF1 degrades myosin heavy chain protein in dexamethasone-treated skeletal muscle. Cell Metabolism 2007; 6:376-85.
22. Cohen S, Brault JJ, Gygi S.P., Glass DJ, Valenzuela DM, Gartner C, et al During muscle atrophy, thick, but not thin, filament components are degraded by MuRF1-dependent ubiquitylation. Journal of Cell Biology 2009; 185: 1083-95.
23. Combaret L, Adegoke OA, Bedard N, Baracos V., Attaix D, Wing SS USP19 is a ubiquitin-specific protease regulated in rat skeletal muscle during catabolic states. American Journal of Physiology: Endocrinology and Metabolism 2005; 288:E693-700.
24. Crawford BA, Liu PY, Kean M.T., Bleasel JF, Handelsman DJ Randomized placebo-controlled trial of androgen effects on muscle and bone in men requiring long-term systemic glucocorticoid treatment. Journal of Clinical Endocrinology and Metabolism 2003; 88:3167-76.
25. Crossland H, Constantin-Teodosiu D, Greenhaff P.L., Gardiner SM Low-dose dexamethasone prevents endotoxaemia-induced muscle protein loss and impairment of carbohydrate oxidation in rat skeletal muscle. Journal of Physiology 2010; 588:1333-47.
26. Dardevet D, Sornet C, Savary I., Debras E, Patureau-Mirand P, Grizard J. Glucocorticoid effects on insulin- and IGF-I-regulated muscle protein metabolism during aging. Journal of Endocrinology 1998; 156:83-9.
27. Decramer M, Lacquet LM, Fagard R, Rogiers P. Corticosteroids contribute to muscle weakness in chronic airflow obstruction. American Journal of Respiratory Critical Care Medicine 1994; 150:11-6.
28. Dehoux M, Van Beneden R, Pasko N, Lause P., Verniers J, Underwood L, et al Role of the insulin-like growth factor I decline in the induction of atrogin-1/MAFbx during fasting and diabetes. Endocrinology 2004; 145:4806-12.
29. Dekhuijzen PN, Gayan-Ramirez G, Bisschop A., de BV, Dom R, Decramer M. Corticosteroid treatment and nutritional deprivation cause a different pattern of atrophy in rat diaphragm. Journal of Applied Physiology 1995; 78: 629-37.
30. Deldicque L, Louis M, Theisen D., Nielens H, Dehoux M, Thissen J.P., et al Increased IGF mRNA in human skeletal muscle after creatine supplementation. Medicine and Science in Sports and Exercise 2005; 37:731-6.
31. Deval D, Mordier S, Obled C., Bechet D, Combaret L, Attaix D., et al Identification of cathepsin L as a differentially expressed message associated with skeletal muscle wasting. Biochemical Journal 2001; 360:143-50.
32. Du J, Wang X, Miereles C., Bailey JL, Debigare R, Zheng B, et al Activation of caspase-3 is an initial step triggering accelerated muscle proteolysis in catabolic conditions. Journal of Clinical Investigation 2004; 113:115-23.
33. Durieux AC, Amirouche A, Banzet S., Koulmann N, Bonnefoy R, Pasdeloup M., et al Ectopic expression of myostatin induces atrophy of adult skeletal muscle by decreasing muscle gene expression. Endocrinology 2007; 148:3140-7.
34. Escolar DM, Hache LP, Clemens P.R., Cnaan A., McDonald CM, Viswanathan V, et al Randomized, blinded trial of weekend vs daily prednisone in Duchenne muscular dystrophy. Neurology 2011; 77:444-52.
35. Evenson AR, Fareed MU, Menconi M.J., Mitchell JC, Hasselgren PO GSK-3beta inhibitors reduce protein degradation in muscles from septic rats and in dexamethasone-treated myotubes. International Journal of Biochemistry and Cell Biology 2005; 37:2226-38.
36. Fang CH, Li BG, James J.H., King JK, Evenson AR, Warden GD, et al. Protein breakdown in muscle from burned rats is blocked by insulin-like growth factor i and glycogen synthase kinase-3beta inhibitors. Endocrinology 2005; 146:3141-9.
37. Ferrando AA, Sheffield-Moore M, Yeckel C.W., Gilkison C., Jiang J, Achacosa A, et al Testosterone administration to older men improves muscle function: molecular and physiological mechanisms. American Journal of Physiology: Endocrinology and Metabolism 2002; 282:E601-7.
38. Fitts RH, Romatowski JG, Peters J.R., Paddon-Jones D, Wolfe RR, Ferrando AA The deleterious effects of bed rest on human skeletal muscle fibers are exacerbated by hypercortisolemia and ameliorated by dietary supplementation. American Journal of Physiology: Cell Physiology 2007; 293:C313-20.
39. Florini JR, Ewton DZ, Coolican SA Growth hormone and the insulin-like growth factor system in myogenesis. Endocrine Reviews 1996; 17:481-517.
40. Fournier M, Huang ZS, Li H, Da X., Cercek B, Lewis MI Insulin-like growth factorI prevents corticosteroid-induced diaphragm muscle atrophy in emphysematous hamsters. American Journal of Physiology: Regulatory, Integrative and Comparative Physiology 2003; 285:R34-43.
41. Frost RA, Lang CH Regulation of insulin-like growth factor-I in skeletal muscle and muscle cells. Minerva Endocrinologica 2003; 28:53-73.
42. Frost RA, Lang CH Multifaceted role of insulin-like growth factors and mammalian target of rapamycin in skeletal muscle. Endocrinology and Metabolism Clinics of North America 2012; 41:297-322, vi.
43. Gayan-Ramirez G., Vanderhoydonc F, Verhoeven G., Decramer M. Acute treatment with corticosteroids decreases IGF-1 and IGF-2 expression in the rat diaphragm and gastrocnemius. American Journal of Respiratory Critical Care Medicine 1999; 159:283-9.
44. Gilson H, Schakman O, Combaret L., Lause P, Grobet L, Attaix D., et al Myostatin gene deletion prevents glucocorticoid-induced muscle atrophy. Endocrinology 2007; 148:452-60.
45. Giorgino F, Pedrini MT, Matera L, Smith RJ Specific increase in p85a expression in response to dexamethasone is associated with inhibition of insulin-like growth factor-I stimulated phosphatidylinositol 3-kinase activity in cultured muscle cells. Journal of Biological Chemistry 1997; 272:7455-63.
46. Goldberg AL, Tischler M, DeMartino G., Griffin G. Hormonal regulation of protein degradation and synthesis in skeletal muscle. Federation Proceedings 1980; 39:31-6.
47. /,5'-cyclic adenosine monophosphate-mediated inhibition of the ubiquitin-proteasome system in skeletal muscle. Endocrinology 2009; 150:5395-404.
48. Grobet L, Pirottin D, Farnir F., Poncelet D, Royo LJ, Brouwers B, et al Modulating skeletal muscle mass by postnatal, muscle-specific inactivation of the myostatin gene. Genesis 2003; 35:227-38.
49. Hasselgren PO. Glucocorticoids and muscle catabolism. Current Opinion in Clinical Nutrition Metabolic Care 1999; 2:201-5.
50. Hasselgren PO, Fischer JE Muscle cachexia: current concepts of intracellular mechanisms and molecular regulation. Annals of Surgery 2001; 233:9-17.
51. Hickson RC, Czerwinski SM, Wegrzyn LE Glutamine prevents downregulation of myosin heavy chain synthesis and muscle atrophy from glucocorticoids. American Journal of Physiology 1995; 268:E730-4.
52. Hickson RC, Oehler DT, Byerly R.J., Unterman TG Protective effect of glutamine from glucocorticoid-induced muscle atrophy occurs without alterations in circulating insulin-like growth factor (IGF)-I and IGF-binding protein levels. Proceedings of the Society for Experimental Biology and Medicine 1997; 216:65-71.
53. Hickson RC, Wegrzyn LE, Osborne D.F., Karl IE Alanyl-glutamine prevents muscle atrophy and glutamine synthetase induction by glucocorticoids. American Journal of Physiology 1996; 271:R1165-72.
54. Hu Z, Wang H, Lee I.H., Du J., Mitch WE Endogenous glucocorticoids and impaired insulin signaling are both required to stimulate muscle wasting under pathophysiological conditions in mice. Journal of Clinical Investigation 2009; 119:3059-69.
55. Huang ZF, Massey JB, Via DP Differential regulation of cyclooxygenase-2 (COX-2) mRNA stability by interleukin-1b (IL-1b) and tumor necrosis factor - a (TNF-α) in human in vitro differentiated macrophages. Biochemical Pharmacology 2000; 59:187-94.
56. Imae M, Fu Z, Yoshida A, Noguchi T, Kato H. Nutritional and hormonal factors control the gene expression of FoxOs, the mammalian homologues of DAF-16. Journal of Molecular Endocrinology 2003; 30:253-62.
57. Inder WJ, Jang C, Obeyesekere V.R., Alford FP Dexamethasone administration inhibits skeletal muscle expression of the androgen receptor and IGF-1-implications for steroid-induced myopathy. Clinical Endocrinology (Oxford) 2010; 73:126-32.
58. Jagoe RT, Redfern CP, Roberts R.G., Gibson GJ, Goodship TH Skeletal muscle mRNA levels for cathepsin B, but not components of the ubiquitin-proteasome pathway, are increased in patients with lung cancer referred forthoracotomy. Clinical Science (London) 2002; 102:353-61.
59. Jefferson LS, Fabian JR, Kimball SR Glycogen synthase kinase-3 is the predominant insulin-regulated eukaryotic initiation factor 2B kinase in skeletal muscle. International Journal of Biochemistry and Cell Biology 1999; 31:191-200.
60. Jellyman JK, Martin-Gronert MS, Cripps R.L., Giussani DA, Ozanne SE, Shen QW, et al Effects of cortisol and dexamethasone on insulin signalling pathways in skeletal muscle of the ovine fetus during late gestation. PLoS One 2012; 7:e52363.
61. Jiang TX, Cairns A, Road J.D., Wilcox PG Effect of the beta-agonist clenbuterol on dexamethasone-induced diaphragm dysfunction in rabbits. American Journal of Respiratory Critical Care Medicine 1996; 154:1778-83.
62. Jones A, Hwang DJ, Narayanan R, Miller D.D., Dalton JT Effects of a novel selective androgen receptor modulator on dexamethasone-induced and hypogonadism-induced muscle atrophy. Endocrinology 2010; 151:3706-19.
63. Kamei Y, Miura S, Suzuki M., Kai Y, Mizukami J, Taniguchi T., et al Skeletal muscle FOXO1 (FKHR) transgenic mice have less skeletal muscle mass, down-regulated Type I (slow twitch/red muscle) fiber genes, and impaired glycemic control. Journal of Biological Chemistry 2004; 279:41114-23.
64. Kanda F, Takatani K, Okuda S., Matsushita T, Chihara K. Preventive effects of insulinlike growth factor-I on steroid-induced muscle atrophy. Muscle Nerve 1999; 22:213-7.
65. Khaleeli AA, Edwards RH, Gohil K, McPhail G, Rennie MJ, Round J, et al Corticosteroid myopathy: a clinical and pathological study. Clinical Endocrinology (Oxford) 1983; 18:155-66.
66. Kimball SR, Jefferson LS Signaling pathways and molecular mechanisms through which branched-chain amino acids mediate translational control of protein synthesis. Journal of Nutrition 2006; 136:227S-31S.
67. Kline WO, Panaro FJ, Yang H, Bodine SC Rapamycin inhibits the growth and muscle-sparing effects of clenbuterol. Journal of Applied Physiology 2007; 102:740-7.
68. Kobayashi H, Kato H, Hirabayashi Y., Murakami H, Suzuki H. Modulations of muscle protein metabolism by branched-chain amino acids in normal and muscle-atrophying rats. Journal of Nutrition 2006; 136:234S-6S.
69. Koh A, Lee MN, Yang Y.R., Jeong H., Ghim J, Noh J, et al C1-Ten is a protein tyrosine phosphatase of IRS-1, regulating IRS-1 stability and muscle atrophy. Molecular and Cellular Biology 2013.
70. Komamura K, Shirotani-Ikejima H, Tatsumi R., Tsujita-Kuroda Y, Kitakaze M, Miyatake K., et al Differential gene expression in the rat skeletal and heart muscle in glucocorticoid-induced myopathy: analysis by microarray. Cardiovascular Drugs and Therapy 2003; 17:303-10.
71. Kostyo JL, Redmond AF Role of protein synthesis in the inhibitory action of adrenal steroid hormones on amino acid transport by muscle. Endocrinology 1966; 79:531-40.
72. Kukreti H, Amuthavalli K, Harikumar A., Sathiyamoorthy S, Feng PZ, Anantharaj R, et al Muscle-specific microRNA1 (miR1) targets heat shock protein 70 (HSP70) during dexamethasone mediated atrophy. Journal of Biological Chemistry 2013; 288(9):6663-78.
73. Kuo T, Lew MJ, Mayba O, Harris C.A., Speed TP, Wang JC Genome-wide analysis of glucocorticoid receptor-binding sites in myotubes identifies gene networks modulating insulin signaling. Proceedings of the National Academy of Sciences of the United States of America 2012; 109:11160-5.
74. Laplante M, Sabatini DM mTOR signaling in growth control and disease. Cell 2012; 149:274-93.
75. Latres E, Amini AR, Amini A.A., Griffiths J., Martin FJ, Wei Y, et al Insulinlike growth factor-1 (IGF-1) inversely regulates atrophy-induced genes via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR) pathway. Journal of Biological Chemistry 2005; 280:2737-44.
76. Lecker SH, Jagoe RT, Gilbert A, Gomes M., Baracos V, Bailey J, et al Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression. FASEBJournal 2004; 18:39-51.
77. Lecker SH, Solomon V, Mitch W.E., Goldberg AL Muscle protein breakdown and the critical role of the ubiquitin-proteasome pathway in normal and disease states. Journal of Nutrition 1999; 129:227S-37S.
78. Lee SW, Dai G, Hu Z., Wang X, Du J, Mitch WE Regulation of muscle protein degradation: coordinated control of apoptotic and ubiquitin-proteasome systems by phosphatidylinositol 3 kinase. Journal of the American Society of Nephrology 2004; 15:1537-45.
79. Li BG, Hasselgren PO, Fang CH Insulin-like growth factor-I inhibits dexamethasone-induced proteolysis in cultured L6 myotubes through PI3K/Akt/GSK-3beta and PI3K/Akt/mTOR-dependent mechanisms. International Journal of Biochemistry and Cell Biology 2005; 37:2207-16.
80. Liu Z, Li G, Kimball S.R., Jahn LA, Barrett EJ Glucocorticoids modulate amino acid-induced translation initiation in human skeletal muscle. American Journal of Physiology: Endocrinology and Metabolism 2004; 287:E275-81.
81. Liu ZQ, Jahn LA, Long W, Fryburg D.A., Wei LP, Barrett EJ Branched chain amino acids activate messenger ribonucleic acid translation regulatory proteins in human skeletal muscle, and glucocorticoids blunt this action. Journal of Clinical Endocrinology and Metabolism 2001; 86:2136-43.
82. Lofberg E, Gutierrez A, Wernerman J., Anderstam B, Mitch WE, Price S.R., et al Effects of high doses of glucocorticoids on free amino acids, ribosomes and protein turnover in human muscle. European Journal of Clinical Investigation 2002; 32:345-53.
83. Lynch CJ. Role of leucine in the regulation of mTOR by amino acids: revelations from structure-activity studies. Journal of Nutrition 2001; 131:861S-5S.
84. Ma K, Mallidis C, Artaza J, Taylor W, Gonzalez-Cadavid N, Bhasin S. Characterization of 5'regulatory region of human myostatin gene: regulation by dexamethasone in vitro. American Journal of Physiology: Endocrinology and Metabolism 2001; 281:E1128-36.
85. Ma K, Mallidis C, Bhasin S., Mahabadi V, Artaza J, Gonzalez-Cadavid N, et al Glucocorticoid-induced skeletal muscle atrophy is associated with upregulation of myostatin gene expression. American Journal of Physiology: Endocrinology and Metabolism 2003; 285:E363-71.
86. Maes K, Testelmans D, Cadot P., Deruisseau K, Powers SK, Decramer M, et al Effects of acute administration of corticosteroids during mechanical ventilation on rat diaphragm. American Journal of Respiratory Critical Care Medicine 2008; 178:1219-26.
87. Mavalli MD, DiGirolamo DJ, Fan Y, Riddle R.C., Campbell KS, van Groen T, et al Distinct growth hormone receptor signaling modes regulate skeletal muscle development and insulin sensitivity in mice. Journal of Clinical Investigation 2010; 120:4007-20.
88. McCroskery S, Thomas M, Maxwell L., Sharma M, Kambadur R. Myostatin negatively regulates satellite cell activation and self-renewal. Journal of Cell Biology 2003; 162:1135-47.
89. McFarlane C, Plummer E, Thomas M., Hennebry A, Ashby M, Ling N., et al Myostatin induces cachexia by activating the ubiquitin proteolytic system through an NF-kappaB-independent, FoxO1-dependent mechanism. Journal of Cell Physiology 2006; 209:501-14.
90. McPherron AC, Lee SJ Double muscling in cattle due to mutations in the myostatin gene. Proceedings of the National Academy of Sciences of the United States of America 1997; 94:12457-61.
91. Menezes LG, Sobreira C, Neder L., Rodrigues-Junior AL, Martinez JA Creatine supplementation attenuates corticosteroid-induced muscle wasting and impairment of exercise performance in rats. Journal of Applied Physiology 2007; 102:698-703.
92. Mills GH, Kyroussis D, Jenkins P, Hamnegard CH, Polkey MI, Wass J, et al. Respiratory muscle strength in Cushing's syndrome. American Journal of Respiratory Critical Care Medicine 1999; 160:1762-5.
93. Mink S, Haenig B, Klempnauer KH Interaction and functional collaboration of p300 and C/EBPbeta. Molecular Cell Biology 1997; 17:6609-17.
94. Mitch WE, Goldberg AL Mechanisms of muscle wasting. The role of the ubiquitin-proteasome pathway. New England Journal of Medicine 1996; 335:1897-905.
95. Morgan SA, Sherlock M, Gathercole L.L., Lavery GG, Lenaghan C, Bujalska IJ, et al 11beta-Hydroxysteroid dehydrogenase type 1 regulates glucocorticoid-induced insulin resistance in skeletal muscle. Diabetes 2009; 58:2506-15.
96. Nakao R, Hirasaka K, Goto J, Ishidoh K, Yamada C, Ohno A, et al. Ubiquitin ligase Cbl-b is a negative regulator for insulin-like growth factor 1 signaling during muscle atrophy caused by unloading. Molecular Cell Biology 2009; 29:4798-811.
97. Nicastro H, Gualano B, de Moraes WM, de SP V, da Luz CR, dos Santos CA, et al Effects of creatine supplementation on muscle wasting and glucose homeostasis in rats treated with dexamethasone. Amino Acids 2012a; 42:1695-701.
98. Nicastro H, Zanchi NE, da Luz CR, de Moraes WM, Ramona P, Siqueira Filho MA, et al Effects of leucine supplementation and resistance exercise on dexamethasone-induced muscle atrophy and insulin resistance in rats. Nutrition 2012b; 28:465-71.
99. Pearen MA, Ryall JG, Maxwell M.A., Ohkura N., Lynch GS, Muscat GE The orphan nuclear receptor, NOR-1, is a target of {beta}-adrenergic signaling in skeletal muscle. Endocrinology 2006; 147:5217-27.
100. Pellegrino MA, D'Antona G, Bortolotto S, Boschi F., Pastoris O, Bottinelli R, et al Clenbuterol antagonizes glucocorticoid-induced atrophy and fibre type transformation in mice. Experimental Physiology 2004; 89:89-100.
101. Penner G, Gang G, Sun X.Y., Wray C., Hasselgren PO C/EBP DNA-binding activity is upregulated by a glucocorticoid-dependent mechanism in septic muscle. American Journal of Physiology: Regulatory, Integrative and Comparative Physiology 2002; 282:R439-44.
102. Perrot V, Rechler MM The coactivator p300 directly acetylates the forkhead transcription factor Foxo1 and stimulates Foxo1-induced transcription. Molecular Endocrinology 2005; 19:2283-98.
103. Polge C, Heng AE, Jarzaguet M, Ventadour S., Claustre A, Combaret L, et al Muscle actin is polyubiquitinylated in vitro and in vivo and targeted for breakdown by the E3 ligase MuRF1. FASEB Journal 2011; 25:3790-802.
104. Porporato PE, Filigheddu N, Reano S., Ferrara M, Angelino E, Gnocchi V.F., et al Acylated and unacylated ghrelin impair skeletal muscle atrophy in mice. Journal of Clinical Investigation 2013; 23(2):611-22.
105. Prezant DJ, Karwa ML, Richner B, Maggiore D., Gentry EI, Cahill J. Gender-specific effects of dexamethasone treatment on rat diaphragm structure and function. Journal of Applied Physiology 1997; 82:125-33.
106. Reisz-Porszasz S., Bhasin S, Artaza J.N., Shen R., Sinha-Hikim I, Hogue A, et al Lower skeletal muscle mass in male transgenic mice with muscle-specific overex-pression of myostatin. American Journal of Physiology: Endocrinology and Metabolism 2003; 285:E876-88.
107. Rieu I, Sornet C, Grizard J., Dardevet D. Glucocorticoid excess induces a prolonged leucine resistance on muscle protein synthesis in old rats. Experimental Gerontology 2004; 39:1315-21.
108. Rodriguez J, Vernus B, Toubiana M., Jublanc E, Tintignac L, Leibovitch S., et al Myostatin inactivation increases myotube size through regulation of translational initiation machinery. Journal of Cellular Biochemistry 2011; 112:3531-42.
109. Rommel C, Bodine SC, Clarke B.A., Rossman R., Nunez L, Stitt TN, et al Mediation of IGF-1-induced skeletal myotube hypertrophy by PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways. Nature Cell Biology 2001; 3:1009-13.
110. Roy BD, Bourgeois JM, Mahoney D.J., Tarnopolsky MA Dietary supplementation with creatine monohydrate prevents corticosteroid-induced attenuation of growth in young rats. Canadian Journal of Physiology and Pharmacology 2002; 80:1008-14.
111. Sacheck JM, Ohtsuka A, McLary S.C., Goldberg AL IGF-I stimulates muscle growth by suppressing protein breakdown and expression of atrophy-related ubiquitin ligases, atrogin-1 and MuRF1. American Journal of Physiology: Endocrinology and Metabolism 2004; 287:E591-601.
112. Salehian B, Mahabadi V, Bilas J., Taylor WE, Ma K. The effect of glutamine on prevention of glucocorticoid-induced skeletal muscle atrophy is associated with myostatin suppression. Metabolism 2006; 55:1239-47.
113. Sandri M, Sandri C, Gilbert A., Skurk C, Calabria E, Picard A., et al Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell 2004; 117:399-412.
114. Schakman O, Gilson H, de C.V., Lause P., Verniers J, Havaux X, et al Insulin-like growth factor-I gene transfer by electroporation prevents skeletal muscle atrophy in glucocorticoid-treated rats. Endocrinology 2005; 146:1789-97.
115. Schakman O, Kalista S, Bertrand L., Lause P, Verniers J, Ketelslegers J.M., et al Role of Akt/GSK-3beta/beta-catenin transduction pathway in the muscle anti-atrophy action of insulin-like growth factor-I in glucocorticoid-treated rats. Endocrinology 2008; 149:3900-8.
116. Schwartz C, Beck K, Mink S., Schmolke M, Budde B, Wenning D., et al Recruitment of p300 by C/EBPbeta triggers phosphorylation of p300 and modulates coactivator activity. EMBO Journal 2003; 22:882-92.
117. Senf SM, Sandesara PB, Reed S.A., Judge AR p300 acetyltransferase activity differentially regulates the localization and activity of the FOXO homologues in skeletal muscle. American Journal of Physiology: Cell Physiology 2011; 300:C1490-501.
118. Shah OJ, Kimball SR, Jefferson LS Acute attenuation of translation initiation and protein synthesis by glucocorticoids in skeletal muscle. American Journal of Physiology: Endocrinology and Metabolism 2000a; 278:E76-82.
119. Shah OJ, Kimball SR, Jefferson LS Among translational effectors, p70S6k is uniquely sensitive to inhibition by glucocorticoids. Biochemical Journal 2000b; 347:389-97.
120. Shimizu N, Yoshikawa N, Ito N., Maruyama T, Suzuki Y, Takeda S., et al Crosstalk between glucocorticoid receptor and nutritional sensor mTOR in skeletal muscle. Cell Metabolism 2011; 13:170-82.
121. Shin YS, Fink H, Khiroya R., Ibebunjo C, Martyn J. Prednisolone-induced muscle dysfunction is caused more by atrophy than by altered acetylcholine receptor expression. Anesthesia and Analgesia 2000; 91:322-8.
122. Short KR, Bigelow ML, Nair KS Short-term prednisone use antagonizes insulin's anabolic effect on muscle protein and glucose metabolism in young healthy people. American Journal of Physiology: Endocrinology and Metabolism 2009; 297:E1260-8.
123. Southgate RJ, Neill B, Prelovsek O, ElOsta A, Kamei Y, Miura S, et al. FOXO1 regulates the expression of 4E-BP1 and inhibits mTOR signaling in mammalian skeletal muscle. Journal of Biological Chemistry 2007; 282:21176-86.
124. 12 muscle cells. American Journal of Physiology: Endocrinology and Metabolism 2001; 280: E221-8.
125. Thomas M, Langley B, Berry C., Sharma M, Kirk S, Bass J., et al Myostatin, a negative regulator of muscle growth, functions by inhibiting myoblast proliferation. Journal of Biological Chemistry 2000; 275:40235-43.
126. Tiao G, Fagan J, Roegner V., Lieberman M, Wang JJ, Fischer J.E., et al Energy-ubiquitin-dependent muscle proteolysis during sepsis in rats is regulated by glucocorticoids. Journal of Clinical Investigation 1996; 97: 339-48.
127. Tischler ME. Effect of the antiglucocorticoid RU38486 on protein metabolism in unweighted soleus muscle. Metabolism 1994; 43:1451-5.
128. Tobimatsu K, Noguchi T, Hosooka T., Sakai M, Inagaki K, Matsuki Y., et al Overexpression of the transcriptional coregulator Cited2 protects against glucocorticoid-induced atrophy of C2C12 myotubes. Biochemical and Biophysical Research Communications 2009; 378:399-403.
129. Tomas FM. The anti-catabolic efficacy of insulin-like growth factor-I is enhanced by its early administration to rats receiving dexamethasone. Journal of Endocrinology 1998; 157:89-97.
130. Tomas FM, Knowles SE, Owens P.C., Chandler CS, Francis GL, Read LC, et al Insulin-like growth factor-I (IGF-I) and especially IGF-I variants are anabolic in dexamethasone-treated rats. Biochemical Journal 1992; 282:91-7.
131. Tomas FM, Munro HN, Young VR. Effect of glucocorticoid administration on the rate of muscle protein breakdown in vivo in rats, as measured by urinary excretion of N tau-methylhistidine. Biochemical Journal 1979; 178:139-46.
132. Uozumi Y, Ito T, Hoshino Y., Mohri T, Maeda M, Takahashi K., et al Myogenic differentiation induces taurine transporter in association with taurine-mediated cytoprotection in skeletal muscles. Biochemical Journal 2006a; 394: 699-706.
133. Uozumi Y, Ito T, Takahashi K., Matsuda T, Mohri T, Kimura Y., et al Myogenic induction of taurine transporter prevents dexamethasone-induced muscle atrophy. Advances in Experimental Medicine and Biology 2006b; 583:265-70.
134. Van Balkom R.H., Dekhuijzen PN, Folgering H.T., Veerkamp JH, Van Moerkerk HT, Fransen JA, et al Anabolic steroids in part reverse glucocorticoid-induced alterations in rat diaphragm. Journal of Applied Physiology 1998; 84: 1492-9.
135. Van Der Velden JL, Langen RC, Kelders M.C., Wouters EF, Janssen-Heininger YM, Schols AM. Inhibition of glycogen synthase kinase-3{beta} activity is sufficient to stimulate myogenic differentiation. American Journal of Physiology: Cell Physiology 2006; 290:C453-62.
136. Verhees KJ, Schols AM, Kelders M.C., Op den Kamp CM, Van Der Velden JL, Langen RC. Glycogen synthase kinase-3beta is required for the induction of skeletal muscle atrophy. American Journal of Physiology: Cell Physiology 2011; 301: C995-1007.
137. Vyas DR, Spangenburg EE, Abraha T.W., Childs TE, Booth FW GSK-3beta negatively regulates skeletal myotube hypertrophy. American Journal of Physiology: Cell Physiology 2002; 283:C545-51.
138. Waddell DS, Baehr LM, van den BJ, Johnsen SA, Reichardt HM, Furlow JD, et al The glucocorticoid receptor and FOXO1 synergistically activate the skeletal muscle atrophy-associated MuRF1 gene. American Journal of Physiology: Endocrinology and Metabolism 2008; 295:E785-97.
139. Wang H, Kubica N, Ellisen L.W., Jefferson LS, Kimball SR Dexamethasone represses signaling through the mammalian target of rapamycin in muscle cells by enhancing expression of REDD1. Journal of Biological Chemistry 2006; 281:39128-34.
140. Wang XH, Zhang L, Mitch WE, LeDoux JM, Hu J, Du J. Caspase-3 cleaves specific 19 S proteasome subunits in skeletal muscle stimulating proteasome activity. Journal of Biological Chemistry 2010; 285:21249-57.
141. Watson ML, Baehr LM, Reichardt H.M., Tuckermann JP, Bodine SC, Furlow JD A cell-autonomous role for the glucocorticoid receptor in skeletal muscle atrophy induced by systemic glucocorticoid exposure. American Journal of Physiology: Endocrinology and Metabolism 2012; 302:E1210-20.
142. Welle S, Bhatt K, Pinkert CA Myofibrillar protein synthesis in myostatin-deficient mice. American Journal of Physiology: Endocrinology and Metabolism 2006; 290:E409-15.
143. Wing SS, Goldberg AL Glucocorticoids activate the ATP-ubiquitin-dependent
144. Wu Y, Zhao W, Zhao J, Pan J, Wu Q, Zhang Y, et al. Identification of androgen response elements in the insulin-like growth factor I upstream promoter. Endocrinology 2007; 148:2984-93.
145. Wu Y, Zhao W, Zhao J, Zhang Y, Qin W, Pan J, et al. REDD1 is a major target of testosterone action in preventing dexamethasone-induced muscle loss. Endocrinology 2010; 151:1050-9.
146. Yamamoto D, Maki T, Herningtyas E.H., Ikeshita N., Shibahara H, Sugiyama Y, et al Branched-chain amino acids protect against dexamethasone-induced soleus muscle atrophy in rats. Muscle Nerve 2010; 41:819-27.
147. Yang H, Menconi MJ, Wei W, Petkova V, Hasselgren PO. Dexamethasone upregulates the expression of the nuclear cofactor p300 and its interaction with C/EBPbeta in cultured myotubes. Journal of Cellular Biochemistry 2005; 94:1058-67.
148. Yang H, Wei W, Menconi M., Hasselgren PO Dexamethasone-induced protein degradation in cultured myotubes is p300/HAT dependent. American Journal of Physiology: Regulatory, Integrative and Comparative Physiology 2007; 292:R337-44.
149. Zamir O, Hasselgren PO, von Allmen D, Fischer JE The effect of interleukin-1 alpha and the glucocorticoid receptor blocker RU 38486 on total and myofibrillar protein breakdown in skeletal muscle. Journal of Surgical Research 1991; 50:579-83.
150. Zhao W, Pan J, Wang X, Wu Y, Bauman WA, Cardozo CP. Expression of the muscle atrophy factor muscle atrophy F-box is suppressed by testosterone. Endocrinology 2008; 149:5449-60.
151. Zhao W, Qin W, Pan J, Wu Y, Bauman WA, Cardozo C. Dependence of dexamethasone-induced Akt/FOXO1 signaling, upregulation of MAFbx, and protein catabolism upon the glucocorticoid receptor. Biochemical and Biophysical Research Communications 2009; 378:668-72.
152. Zheng B, Ohkawa S, Li H., Roberts-Wilson TK, Price SR FOXO3a mediates signaling crosstalk that coordinates ubiquitin and atrogin-1/MAFbx expression during glucocorticoid-induced skeletal muscle atrophy. FASEB Journal 2010; 24:2660-9.